MAZEMaze Therapeutics, Inc.
Is it safe?
Caution warranted: heavy debt (BB) and big price swings.
Insiders were net sellers (-$6.1M, 90 days to Oct 8, 2026), selling is often routine.
Net cash, but unprofitable, speculative. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -57% · now 48% below its 52-week high.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can MAZE take a bad year?
Maze Therapeutics, Inc. holds $372M more cash than debt, and is burning $27M a quarter, about 3.9 years of cover.
Net cash
- Net debt / EBITDA
- net cash
Net debt / EBITDA · no net borrowings to measure against earnings
- Cash runway
- 3.9 years
Cash runway · burning $27M a quarter at the current rate
- Annualised volatility
- 91%
Annualised volatility · three times the market's own swing
Details›
- Total debtQ2 2026
- $39M
- Cash and short-term investments
- $411M
- Net cash
- $372M
- EBITDA, trailing twelve months
- −$144M
- Operating profit, trailing twelve months
- −$146M
- Debt / equity
- 0.09×
- Annualised volatilitytwo years of daily moves
- 91%
- Worst drawdown on file
- −57%
- Below its 52-week high
- 48%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Biotechnology
The closest names by size in the same industry